Shenzhen Core Medical Technology Co., Ltd. (hereinafter referred to as"Core Medical") announced the completionUltra1Billion US dollarsDRound of financing, this round led by Loyal Valley Capital, Legend Capital, and Aramco Ventures.Prosperity7 Ventures(P7)Cornerstone Capital and well-known industry investors jointly led the investment, with Delian Capital and Lianxin Capital following up.。

Against the backdrop of the overall cooling financing market, Core Medical stands out with its exceptional performance in the artificial heart field.，Successfully attracted the attention of many well-known investment institutions at home and abroad, becoming the focus of capital pursuit.Completed the largest market-based financing in China's innovative medical device sector for 2025.So, what are the outstanding features of this innovative medical device company located in Shenzhen that enable it to stand out in the fiercely competitive market? 

As one of the artificial heart enterprises in China,"One of the 'Four Little Dragons',"Although Core Medical was the last player to receive approval from the National Medical Products Administration (NMPA), its commercial performance in the past two years has been extremely impressive, achieving a remarkable leap forward.Submitted an impressive report card:

• Its first productCorheart 6 ranked first in market share within its first year on the market;

• As of now,The cumulative implantation volume of Corheart 6 has exceeded 700 units;

• Achieved commercial implant volume, cumulative implant volume, and market share"Triple First Place."

In the field of high-end implantable medical devices, the technological advancement and reliability fundamentally determine the market performance of the products."The commercial logic of 'the first to reach the city tower becomes king' does not apply."Especially for life-and-death products like artificial hearts, technological advantages are the core competitiveness.

Core Medical'sCorheart 6 adopts a breakthrough axial full magnetic levitation design and control technology,Compared with similar products, it has the advantages of being smaller, lighter, and better.Weighing only 90g for the pump and 800g for the peripherals, this product can provide patients with a battery life of up to 33 hours. From the target population, intraoperative implantation, to daily living experience, Corheart 6 has become the superior choice due to its technical advantages, which is also the core driving force behind its commercial success.

Core Medical has not been satisfied with its existing achievements but has continued to expand the product boundaries and industry ceiling. Relying on its axial full magnetic levitation technology platform, Core Medical has continuously explored new treatment areas, from applications for pediatric heart failure to integrated solutions for biventricular heart failure.

In the field of interventional ventricular assist, itsCorVad Series of Interventional Ventricular Assist Devices Enter Registration Phase, Expected to Receive NMPA Approval for Market Launch Soon. This series of products utilizes independently designed micro motors and control technology, achieving greater flow and more stable performance with a smaller outer diameter, significantly reducing the risk of blood damage, and supporting longer clinical use. Compared with existing foreign products, it has significant advantages.

Overall, Core Medical's product pipeline is deep and comprehensive, covering both implantable and interventional ventricular assist treatment areas to meet the needs of different patient groups — from left-sided to biventricular support, and from short-term assistance to long-term solutions. Core Medical has achieved leapfrog development, and its leading position in the industry has become evident.

In the global ventricular assist device market, Abbott'sHeartMate 3And Johnson & Johnson'sImpellaRespectively occupy an absolute monopoly position in the implantation and interventional fields.HeartMate 3The global total implant volume has broken through3.5Ten thousand units, andImpellaAnnual sales up to14Billion USD. In the European and American markets,ImpellaAndHeartMate 3The combined use of treatments for heart failure patients is also rapidly gaining popularity.Core Medical, as the only company in the world that simultaneously develops implantable and interventional ventricular assist devices, its commercial value and technological sophistication are self-evident.In advancing its internationalization strategy, Core Medical has also demonstrated steady and pragmatic progress.

• 2024Year, Core Medical launched in Austria, GermanyCorheart 6Clinical trial enrollment, becoming the first company in China to conduct high-risk Class III active implantable device clinical trials in Europe and the United States;

• First Integrated Dual-Core Product Completed in Hannover, GermanyDuoCorHumanitarian Aid Implant;

  
  

It is worth mentioning that, against the backdrop of escalating geopolitical conflicts between China and the U.S. and the impact of tariff wars on trade patterns, Core Medical's Europe-focused internationalization strategy appears particularly robust and pragmatic. The European market boasts strong payment capabilities and a relatively stable market environment.

Core Medical relies on"The product layout and superior performance of 'having what others don’t, and excelling where others have,' along with the synergistic effect of its implantable and interventional products,"Expected to become the first international leader in the field of heart failure and circulatory support to step out of China.Its internationalization potential is enormous.